Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
181.9(c) 186.19(c) 186.28(c) 184.12(c) 182.96(c) Last
2 211 464 3 753 749 2 580 235 2 563 623 3 179 172 Volume
-0.61% +2.36% +0.05% -1.16% -0.63% Change
More quotes
Financials ($)
Sales 2017 22 864 M
EBIT 2017 11 817 M
Net income 2017 8 137 M
Finance 2017 4 380 M
Yield 2017 2,46%
Sales 2018 22 996 M
EBIT 2018 11 874 M
Net income 2018 8 161 M
Finance 2018 6 837 M
Yield 2018 2,64%
P/E ratio 2017 16,51
P/E ratio 2018 16,19
EV / Sales2017 5,65x
EV / Sales2018 5,51x
Capitalization 134 B
More Financials
Company
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses.The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.Its products include... 
Sector
Pharmaceuticals
Calendar
10/25 | 10:01pmEarnings Release
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
10/20 AMGEN : Announces Webcast of 2017 Third Quarter Financial Results
10/20 AMGEN : Engineered protein treatment found to reduce obesity in mice, rats and p..
10/20AMGEN, INC. : quaterly earnings release
10/20 AMGEN : and Boston Children's Hospital Enter a Collaboration to Find New Genes A..
10/19 AMGEN : Data on Lupus Reported by Researchers at Amgen (Safety, pharmacokinetics..
10/18 AMGEN : Kári Stefánsson Honored with Prestigious Award for Significant Contribut..
10/16 AMGEN : And Boston Children's Hospital Enter A Collaboration To Find New Genes A..
10/12 AMGEN : Wins Reprieve on Its 2nd-Best-Selling Drug
10/12 AMGEN : Reports on Biosimilars from Amgen Provide New Insights (A phase I, rando..
10/12 Loncar Cancer Immunotherapy Index Announces Merger Replacements
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on AMGEN 
AMGEN, INC. - 2016
Expectation of a turn-around
BUY
AMGEN, INC. - 2016
Big comeback of buyers
BUY
More Strategies
Latest Tweets
11:11aAmgen Inc. $AMGN Stock Rating Reaffirmed by BMO Capital Markets  
10:52aAmgen Inc. $AMGN Holdings Lifted by Cadinha & Co. LLC  
10:51aAmgen Inc. $AMGN Holdings Lowered by Harel Insurance Investments & Financ.. 
10/21Wheatland Advisors Inc. Continues to Hold Stake in Amgen Inc. $AMGN  
10/21Amgen Announces Webcast of 2017 Third Quarter Financial Results  
More tweets
Qtime:240
News from SeekingAlpha
10/21 Stocks to watch next week
10/20 Celgene selloff weighs on biotechs, IBB down 1%
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/18 Delta Air Lines Is Cheap - Cramer's Lightning Round (10/17/17)
10/17 VALUE SYSTEM : Amgen Looks Undervalued
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 190 $
Spread / Average Target 4,1%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN27.41%133 501
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223